科研成果详情

题名Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
作者
发表日期2023-02-05
发表期刊Chinese medical journal   影响因子和分区
语种英语
原始文献类型Journal Article
关键词Apoptosis Diagnosis Cytokeratin-18 Liver histology Non-alcoholic steatohepatitis Non-alcoholic fatty liver disease
其他关键词FATTY LIVER-DISEASE ; NONINVASIVE ASSESSMENT ; PLASMA CYTOKERATIN-18 ; BIOMARKER ; TRANSPLANTATION ; METAANALYSIS ; ASSOCIATION ; FIBROSIS ; OBESE
摘要Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may be useful in diagnosing NASH, but results across studies have been inconsistent. We aimed to identify the utility of CK-18 M30 concentrations as an alternative to liver biopsy for non-invasive identification of NASH., Individual data were collected from 14 registry centers on patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD), and in all patients, circulating CK-18 M30 levels were measured. Individuals with a NAFLD activity score (NAS) ≥5 including a score of ≥1 for each of steatosis, ballooning, and lobular inflammation were diagnosed as having definite NASH; individuals with a NAS ≤2 and no fibrosis were diagnosed as having non-alcoholic fatty liver (NAFL)., A total of 2571 participants were screened, and 1008 (153 with NAFL and 855 with NASH) were finally enrolled. Median CK-18 M30 levels were higher in patients with NASH than in those with NAFL (mean difference 177 U/L; standardized mean difference [SMD]: 0.87 [0.69-1.04]). There was an interaction between CK-18 M30 levels and serum alanine aminotransferase, body mass index (BMI), and hypertension (P < 0.001, P = 0.026 and P = 0.049, respectively). CK-18 M30 levels were positively associated with histological NAS in most centers. The area under the receiver operating characteristics (AUROC) for NASH was 0.750 (95% confidence intervals: 0.714-0.787), and CK-18 M30 at Youden's index maximum was 275.7 U/L. Both sensitivity (55% [52%-59%]) and positive predictive value (59%) were not ideal., This large multicenter registry study shows that CK-18 M30 measurement in isolation is of limited value for non-invasively diagnosing NASH.
资助项目National Natural Science Foundation of China [82070588]; High-Level Creative Talents from the Department of Public Health in Zhejiang Province [S2032102600032]; Project of New Century 551 Talent Nurturing in Wenzhou; University School of Medicine of Verona, Verona, Italy; Southampton NIHR Biomedical Research Centre, UK [IS-BRC-20004]; Robert W. Storr Bequest; National Health and Medical Research Council of Australia (NHMRC) [APP1053206, APP2001692, APP1107178, APP1108422]
出版者LIPPINCOTT WILLIAMS & WILKINS
ISSN0366-6999
EISSN2542-5641
卷号136期号:3页码:341-350
DOI10.1097/CM9.0000000000002603
页数10
WOS类目Medicine, General & Internal
WOS研究方向General & Internal Medicine
WOS记录号WOS:000960673000010
收录类别PUBMED ; SCIE ; SCOPUS
URL查看原文
PubMed ID36848175
SCOPUSEID2-s2.0-85151312417
通讯作者地址[Zheng, Minghua]Department of Hepatology,MAFLD Research Center,First Affiliated Hospital of Wenzhou Medical University,No. 2, Fuxue Lane, Wenzhou,Zhejiang,325000,China
Scopus学科分类Medicine (all)
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/172868
专题附属第一医院
温州医科大学
第一临床医学院(信息与工程学院)、附属第一医院_内科学_感染内科
通讯作者Zheng, Minghua
作者单位
1.Department of Biostatistics and Medical Record,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,325000,China;
2.Department of Hepatology,MAFLD Research Center,First Affiliated Hospital of Wenzhou Medical University,No. 2, Fuxue Lane, Wenzhou,Zhejiang,325000,China;
3.Service d'Hépato-Gastroentérologie et Oncologie Digestive,Centre Hospitalier Universitaire d'Angers,Angers,France;
4.Laboratoire HIFIH,UPRES EA3859,SFR ICAT 4208,Université d'Angers,Angers,France;
5.Université Côte d'Azur,CHU,INSERM,U1065, C3M,Nice,06204,France;
6.Gastroenterology and Hepatology Unit,Department of Medicine,Faculty of Medicine,University of Malaya,Kuala Lumpur,Malaysia;
7.Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital and University of Sydney,Sydney,Australia;
8.Department of Gastroenterology,School of Medicine,Marmara University,Istanbul,Turkey;
9.Department of Gastroenterology,School of Medicine,Recep Tayyip Erdoǧan University,Rize,Turkey;
10.Department of Medicine and Therapeutics,Chinese University of Hong Kong,999077,Hong Kong;
11.Department of Gastroenterology,Xinhua Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,200000,China;
12.University Clinic for Visceral Surgery and Medicine,Inselspital,University Hospital Bern,Bern,Switzerland;
13.Graduate School for Health Sciences,University of Bern,Bern,Switzerland;
14.Academic Department of Gastroenterology,Medical School of National and Kapodistrian University of Athens,General Hospital of Athens "laiko",Athens,Greece;
15.Department of Gastroenterology,Ruijin Hospital,Shanghai,200000,China;
16.Metabolic Liver Research Program I,Department of Medicine,University Medical Center Mainz,Mainz,Germany;
17.Affiliated Hospital of Hangzhou Normal University,Hangzhou,Zhejiang,310000,China;
18.Tianjin Second People's Hospital,Tianjin,300000,China;
19.Division of Gastroenterology and Hepatology,Key Laboratory of Gastroenterology and Hepatology,Ministry of Health,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai Institute of Digestive Disease,Shanghai,200000,China;
20.Southampton National Institute for Health and Care Research Biomedical Research Centre,University Hospital Southampton,Southampton General Hospital,Southampton,United Kingdom;
21.Section of Endocrinology,Diabetes and Metabolism,Department of Medicine,University and Azienda Ospedaliera Universitaria Integrata of Verona,Verona,Italy;
22.Xi'An Medical University,Xi'an,Shaanxi,710000,China;
23.Institute of Hepatology,Wenzhou Medical University,Wenzhou,Zhejiang,325000,China;
24.Key Lab. of Diagn. and Treatment for the Development of Chronic Liver Disease in Zhejiang Province,Wenzhou,Zhejiang,325000,China
第一作者单位附属第一医院
通讯作者单位附属第一医院
第一作者的第一单位附属第一医院
推荐引用方式
GB/T 7714
Zhang, Huai,Rios, Rafael S.,Boursier, Jerome,et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study[J]. Chinese medical journal,2023,136(3):341-350.
APA Zhang, Huai., Rios, Rafael S.., Boursier, Jerome., Anty, Rodolphe., Chan, Wah-Kheong., ... & Zheng, Minghua. (2023). Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. Chinese medical journal, 136(3), 341-350.
MLA Zhang, Huai,et al."Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study".Chinese medical journal 136.3(2023):341-350.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Zhang, Huai]的文章
[Rios, Rafael S.]的文章
[Boursier, Jerome]的文章
百度学术
百度学术中相似的文章
[Zhang, Huai]的文章
[Rios, Rafael S.]的文章
[Boursier, Jerome]的文章
必应学术
必应学术中相似的文章
[Zhang, Huai]的文章
[Rios, Rafael S.]的文章
[Boursier, Jerome]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。